ROMAZARIT SODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H15ClNO4.Na
Molecular Weight	331.727
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].CC1=C(COC(C)(C)C([O-])=O)OC(=N1)C2=CC=C(Cl)C=C2

InChI

InChIKey=IXEKPMAYILRTFK-UHFFFAOYSA-M

InChI=1S/C15H16ClNO4.Na/c1-9-12(8-20-15(2,3)14(18)19)21-13(17-9)10-4-6-11(16)7-5-10;/h4-7H,8H2,1-3H3,(H,18,19);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	C15H15ClNO4
Molecular Weight	308.737
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1995900 | https://www.ncbi.nlm.nih.gov/pubmed/7619674 | https://www.ncbi.nlm.nih.gov/pubmed/16125391

Romazarit, (Ro 31-3948, 7), 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methylpropionic acid is a substituted heterocyclic alkoxypropionic acid. Romazarit was considered to be a potential disease-modifying antirheumatic drug. Romazarit was withdrawn due to its toxicity profile.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
inflammatory response 47 Target ID: GO:0006954 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2156999 \| https://www.ncbi.nlm.nih.gov/pubmed/1995900	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Rheumatoid arthritis 316 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1550907 https://www.ncbi.nlm.nih.gov/pubmed/7619674 https://www.arthritisresearch.us/side-effects/romazarit.html	Primary		Phase II 1132	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
144 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2088768	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:		ROMAZARIT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
958 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2088768	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:		ROMAZARIT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
1500 mg single, oral Highest studied dose Dose: 1500 mg Route: oral Route: single Dose: 1500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2088768 Page: p.320	healthy, ,ADULT n = 6 Health Status: healthy Age Group: ,ADULT Sex: M Food Status: FASTED Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/2088768 Page: p.320	Sources: https://pubmed.ncbi.nlm.nih.gov/2088768 Page: p.320

Sourcing

Vendor/Aggregator	ID	URL
Alfa Chemistry	36848	http://www.alfa-chemistry.com/search.aspx?q=36848
Alfa Chemistry	ACM109543762	http://www.alfa-chemistry.com/search.aspx?q=ACM109543762
Compound Cloud	71321
MuseChem	M008133	https://www.musechem.com/product/M008133.html
Tetrahedron	TS60829	http://www.thsci.com/search.do?q=TS60829

PubMed

Title	Date	PubMed
Romazarit: a potential disease-modifying antirheumatic drug.	1991 Feb	1995900

Patents

Sample Use Guides

In Vivo Use Guide

patients with rheumatoid arthritis: 200 mg or 450 mg every 12 h for up to 24 weeks, 100 mg t.i.d., 350 mg b.i.d., or 350 mg t.i.d., for 6 days.

Route of Administration: Oral

In Vitro Use Guide

In vitro romazarit was an extremely weak inhibitor of prostaglandin synthetase activity in both sheep seminal vesicle (IC50 6500 microM) and rat renal medulla (IC50 greater than 300 microM) cell-free preparations.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:09:32 GMT 2023` Edited by `admin` on `Sat Dec 16 10:09:32 GMT 2023`
Record UNII	TK7BS24A7A
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ROMAZARIT SODIUM

Common Name

English

SODIUM 2-((2-(4-CHLOROPHENYL)-4-METHYL-1,3-OXAZOL-5-YL)METHOXY)-2-METHYLPROPANOATE

Systematic Name

English

PROPANOIC ACID, 2-((2-(4-CHLOROPHENYL)-4-METHYL-5-OXAZOLYL)METHOXY)-2-METHYL-, SODIUM SALT

Common Name

English

RO-31-3948/002

Code

English

Code System Code Type Description

CAS

109544-09-4

Created by admin on Sat Dec 16 10:09:32 GMT 2023 , Edited by admin on Sat Dec 16 10:09:32 GMT 2023

PRIMARY

FDA UNII

TK7BS24A7A

Created by admin on Sat Dec 16 10:09:32 GMT 2023 , Edited by admin on Sat Dec 16 10:09:32 GMT 2023

PRIMARY

EPA CompTox

DTXSID30911236

Created by admin on Sat Dec 16 10:09:32 GMT 2023 , Edited by admin on Sat Dec 16 10:09:32 GMT 2023

PRIMARY

PUBCHEM

23663984

Created by admin on Sat Dec 16 10:09:32 GMT 2023 , Edited by admin on Sat Dec 16 10:09:32 GMT 2023

PRIMARY

Related Record Type Details


					CN68E94R2X

ROMAZARIT

PARENT -> SALT/SOLVATE

Amount:

Related Record Type Details


					CN68E94R2X

ROMAZARIT

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/1995900 | https://www.ncbi.nlm.nih.gov/pubmed/7619674 | https://www.ncbi.nlm.nih.gov/pubmed/16125391

Originator

Approval Year

Targets

Conditions

Approved Use

Cmax

AUC

Doses

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1995900 | https://www.ncbi.nlm.nih.gov/pubmed/7619674 | https://www.ncbi.nlm.nih.gov/pubmed/16125391

C_max